<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font20 { font-size : 20; } .font25 { font-size : 25; } .font29 { font-size : 29; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font29">the </span>
   <span class="font25">with </span>
   <span class="font20">HCV </span>
   <span class="font18">patients </span>
   <span class="font17">disease </span>
   <span class="font16">for </span>
   <span class="font16">glomerular </span>
   <span class="font15">The </span>
   <span class="font15">antiviral </span>
   <span class="font14">kidney </span>
   <span class="font14">(%) </span>
   <span class="font14">[]. </span>
   <span class="font14">therapy </span>
   <span class="font14">{background </span>
   <span class="font13">been </span>
   <span class="font13">clinical </span>
   <span class="font13">after </span>
   <span class="font13">hepatitis </span>
   <span class="font13">treatment </span>
   <span class="font12">cryoglobulinemic </span>
   <span class="font12">margin </span>
   <span class="font12">have </span>
   <span class="font12">{border-style </span>
   <span class="font12">DAAs </span>
   <span class="font12">was </span>
   <span class="font12">chronic </span>
   <span class="font12">glomerulonephritis </span>
   <span class="font12">px;} </span>
   <span class="font12">that </span>
   <span class="font12">virus </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">HCV-associated </span>
   <span class="font12">HCV-related </span>
   <span class="font12">are </span>
   <span class="font12">has </span>
   <span class="font12">infection </span>
   <span class="font12">mixed </span>
   <span class="font12">associated </span>
   <span class="font12">cryoglobulinemia </span>
   <span class="font12">response </span>
   <span class="font11">RTX </span>
   <span class="font11">were </span>
   <span class="font11">from </span>
   <span class="font11">vasculitis </span>
   <span class="font11">DAAs. </span>
   <span class="font11">agents </span>
   <span class="font11">immunosuppressive </span>
   <span class="font11">CKD </span>
   <span class="font11">Kidney </span>
   <span class="font11">between </span>
   <span class="font11">mg) </span>
   <span class="font11">mg/ </span>
   <span class="font11">renal </span>
   <span class="font11">&amp;lt; </span>
   <span class="font11">IFN </span>
   <span class="font11">al. </span>
   <span class="font11">and/or </span>
   <span class="font11">immune </span>
   <span class="font11">HCV. </span>
   <span class="font11">Table </span>
   <span class="font11">Treatment </span>
   <span class="font11">frequency </span>
   <span class="font11">proteinuria </span>
   <span class="font11">regimens </span>
   <span class="font11">treated </span>
   <span class="font11">viral </span>
   <span class="font11">Disease </span>
   <span class="font11">HCV-induced </span>
   <span class="font11">all </span>
   <span class="font11">direct-acting </span>
   <span class="font11">genotype </span>
   <span class="font11">membranoproliferative </span>
   <span class="font11">patient </span>
   <span class="font11">px; </span>
   <span class="font11">received </span>
   <span class="font11">review </span>
   <span class="font11">rituximab </span>
   <span class="font11">studies </span>
   <span class="font11">virological </span>
   <span class="font11">who </span>
   <span class="font11">{font-family </span>
   <span class="font10">Glomerular </span>
   <span class="font10">However, </span>
   <span class="font10">RNA </span>
   <span class="font10">SVR </span>
   <span class="font10">font-size </span>
   <span class="font10">given </span>
   <span class="font10">important </span>
   <span class="font10">not </span>
   <span class="font10">noted </span>
   <span class="font10">observed </span>
   <span class="font10">plus </span>
   <span class="font10">serum </span>
   <span class="font10">severe </span>
   <span class="font10">should </span>
   <span class="font10">stage </span>
   <span class="font10">syndrome </span>
   <span class="font10">therapies </span>
   <span class="font10">which </span>
   <span class="font10">DAA-based </span>
   <span class="font10">Hepatitis </span>
   <span class="font10">Patients </span>
   <span class="font10">[,]. </span>
   <span class="font10">adverse </span>
   <span class="font10">but </span>
   <span class="font10">combinations </span>
   <span class="font10">complexes </span>
   <span class="font10">deposits </span>
   <span class="font10">disease. </span>
   <span class="font10">double; </span>
   <span class="font10">due </span>
   <span class="font10">even </span>
   <span class="font10">following </span>
   <span class="font10">general </span>
   <span class="font10">shows </span>
   <span class="font10">sustained </span>
   <span class="font10">systematic </span>
   <span class="font10">than </span>
   <span class="font10">two </span>
   <span class="font10">type </span>
   <span class="font10">virus-associated </span>
   <span class="font10">Antiviral </span>
   <span class="font10">HCV-Related </span>
   <span class="font10">Nephrotic </span>
   <span class="font10">RBV </span>
   <span class="font10">[], </span>
   <span class="font10">activity </span>
   <span class="font10">baseline </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cause </span>
   <span class="font10">course </span>
   <span class="font10">damage </span>
   <span class="font10">direct </span>
   <span class="font10">dose </span>
   <span class="font10">drugs </span>
   <span class="font10">efficacy </span>
   <span class="font10">events </span>
   <span class="font10">factor </span>
   <span class="font10">found </span>
   <span class="font10">frequent </span>
   <span class="font10">including </span>
   <span class="font10">liver </span>
   <span class="font10">mL/min/. </span>
   <span class="font10">manifestations </span>
   <span class="font10">many </span>
   <span class="font10">most </span>
   <span class="font10">population </span>
   <span class="font10">solid; </span>
   <span class="font10">some </span>
   <span class="font10">symptomatic </span>
   <span class="font10">this </span>
   <span class="font10">three </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(Table </span>
   <span class="font10">CI, </span>
   <span class="font10">Clinical </span>
   <span class="font10">Cryoglobulinemic </span>
   <span class="font10">HCV-MCS </span>
   <span class="font10">HCV-infected </span>
   <span class="font10">MCS </span>
   <span class="font10">Mesangial </span>
   <span class="font10">These </span>
   <span class="font10">according </span>
   <span class="font10">acting </span>
   <span class="font10">additional </span>
   <span class="font10">administration </span>
   <span class="font10">authors </span>
   <span class="font10">based </span>
   <span class="font10">bold </span>
   <span class="font10">cells </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">diseases </span>
   <span class="font10">eGFR </span>
   <span class="font10">effective </span>
   <span class="font10">elbasvir/grazoprevir </span>
   <span class="font10">em; </span>
   <span class="font10">estimate </span>
   <span class="font10">haematuria </span>
   <span class="font10">high </span>
   <span class="font10">includes </span>
   <span class="font10">increased </span>
   <span class="font10">inhibitors </span>
   <span class="font10">isolated </span>
   <span class="font10">its </span>
   <span class="font10">large </span>
   <span class="font10">long-term </span>
   <span class="font10">low </span>
   <span class="font10">management </span>
   <span class="font10">mono-therapy </span>
   <span class="font10">more </span>
   <span class="font10">now </span>
   <span class="font10">number </span>
   <span class="font10">pathogens---t_Table </span>
   <span class="font10">patients) </span>
   <span class="font10">pt;} </span>
   <span class="font10">rates </span>
   <span class="font10">recent </span>
   <span class="font10">regimen </span>
   <span class="font10">relationship </span>
   <span class="font10">remission </span>
   <span class="font10">report </span>
   <span class="font10">reports </span>
   <span class="font10">several </span>
   <span class="font10">side </span>
   <span class="font10">syndrome, </span>
   <span class="font10">these </span>
   <span class="font10">transplant </span>
   <span class="font10">unique </span>
   <span class="font10">vasculitic </span>
   <span class="font10">while </span>
  </p>
 </body>
</html>
